Literature DB >> 27036341

Non-randomised Ebola trials--lessons for optimal outbreak research.

Giuseppe Ippolito1, Simone Lanini2, Philippe Brouqui3, Antonino Di Caro2, Francesco Vairo2, Francesco Maria Fusco2, Sanjeev Krishna4, Maria Rosaria Capobianchi2, Henry Kyobe-Bosa5, Vincenzo Puro2, Roman Wölfel6, Tatjana Avsic-Zupanc7, John P A Ioannidis8, Gina Portella9, Peter Kremsner10, Osman Dar11, Matthew Bates12, Alimuddin Zumla13.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27036341     DOI： 10.1016/S1473-3099(16)00132-8

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  3 in total

1.  A multi-source adaptive platform design for testing sequential combinatorial therapeutic strategies.

Authors:  Alexander M Kaizer; Brian P Hobbs; Joseph S Koopmeiners
Journal:  Biometrics       Date:  2018-01-22       Impact factor: 2.571

Review 2.  A Systematic Review of Ebola Treatment Trials to Assess the Extent to Which They Adhere to Ethical Guidelines.

Authors:  Thomas Richardson; Andrew McDonald Johnston; Heather Draper
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

3.  Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial.

Authors:  Yaseen M Arabi; Adel Alothman; Hanan H Balkhy; Abdulaziz Al-Dawood; Sameera AlJohani; Shmeylan Al Harbi; Suleiman Kojan; Majed Al Jeraisy; Ahmad M Deeb; Abdullah M Assiri; Fahad Al-Hameed; Asim AlSaedi; Yasser Mandourah; Ghaleb A Almekhlafi; Nisreen Murad Sherbeeni; Fatehi Elnour Elzein; Javed Memon; Yusri Taha; Abdullah Almotairi; Khalid A Maghrabi; Ismael Qushmaq; Ali Al Bshabshe; Ayman Kharaba; Sarah Shalhoub; Jesna Jose; Robert A Fowler; Frederick G Hayden; Mohamed A Hussein
Journal:  Trials       Date:  2018-01-30       Impact factor: 2.279
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.